

CURRENT REPORT 31/2022

December 15, 2022

Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("**Company**", "**Issuer**") with reference to Current Report No 22/2022 of 5 October 2022, Current Report No 28/2022 of 2 December 2022 and Current Report No 29/2022 of 7 December 2022, wherein the Issuer announced the issuance within the limits of the authorized capital of up to 4,764,674 (in words: four million seven hundred sixty-four thousand six hundred seventy-four) series J shares ("**Series J Shares**") which shall be offered under a public offering conducted under a prospectus approved by the Financial Supervision Authority on 7 December 2022 (the "**Offering**"), (the "**Prospectus**"), the Issuer announces that on 15 December 2022, following the completion of the book-building process for Series J Shares, the Management Board of the Company:

1. determined the final issue price of Series J Shares for retail and institutional investors at PLN 55 (in words: fifty five zloty) ("**Final Issue Price**");
2. in connection with the determination of the Final Issue Price for Series J Shares at PLN 55 and in accordance with the provisions of the investment agreement executed by the Issuer with BioNTech SE, with its registered office in Mainz ("**BioNTech**"), of which the Issuer informed in Current Report No 26 dated 30 November 2022, and in accordance with the provisions of the Prospectus, the Management Board of the Company determined that the issue price of Series J Shares in a tranche to be taken up by BioNTech shall be PLN 48.86 (in words: forty-eight zlotys eighty-six groszy) per Series J Share (the "**BioNTech Share Price**");
3. determined the final amount by which the Company's share capital shall be increased through the issuance of Series J Shares at PLN 1,905,869.60 (in words: one million, nine hundred and five thousand, eight hundred and sixty-nine zlotys and sixty groszy), and accordingly, the final number of Series J Shares which shall be offered in the Offering at 4,764,674 (in words: four million, seven hundred and sixty-four thousand, six hundred and seventy-four) Series J Shares, of which:

- 1) 30,753 (in words: thirty thousand seven hundred fifty three) Series J Shares will be offered in the Offering to retail investors,
- 2) 2,816,484 (in words: two million eight hundred sixteen thousand four hundred eighty four) Series J Shares will be offered in the Offering to institutional investors,
- 3) 1,917,437 (in words: one million nine hundred seventeen thousand four hundred thirty seven) Series J Shares will be offered in the Offering to BioNTech.

Furthermore, the Management Board of the Company informs that on 15 December 2022 the Supervisory Board of the Company approved the Final Issue Price and the BioNTech Share Price.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board